Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 8, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.2K

Optimising Recovery of Hepatic Regulatory T Cells: A Practical Guide Using ARTC2 Blockade.

Caitlin Abbott1, Violette Mouro1,2, Chiara Perucchini2

  • 1Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.

European Journal of Immunology
|December 19, 2025
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lymphoid tissue chemokines limit priming duration to preserve CD8<sup>+</sup> T cell functionality.

Science (New York, N.Y.)·2026
Same author

Kupffer cells in liver homeostasis and disease: from immune sentinels to metabolic gatekeepers.

Nature reviews. Immunology·2026
Same author

Abortive infection: T cells as early, antibody-independent defenders.

Nature reviews. Immunology·2026
Same author

Platelet-derived integrin- and tetraspanin-enriched tethers exacerbate severe inflammation.

Science (New York, N.Y.)·2026
Same author

Guidelines for T cell nomenclature.

Nature reviews. Immunology·2025
Same author

The co-inhibitory receptor TIGIT promotes tissue-protective functions in T cells.

Nature immunology·2025
Same journal

Fast Generation of F(Ab')<sub>2</sub> Fragments From Human IgG Using Fc-Fused IgG-Degrading Enzyme.

European journal of immunology·2026
Same journal

Generation of Regulatory T Cells Against Islet Neoantigen.

European journal of immunology·2026
Same journal

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

European journal of immunology·2026
Same journal

Special Issue: yEFIS 3rd Symposium.

European journal of immunology·2026
Same journal

CRISPR/Cas9-Mediated Gene Knockout Reveals a Nonredundant Role for p16<sup>INK4A</sup> in Controlling TCR-Dependent and Independent CD8 T Cell Expansion.

European journal of immunology·2026
Same journal

Induction of Humoral and Cellular Immunity After SARS-CoV-2 JN.1 Vaccination in Individuals With and Without Prior Infection.

European journal of immunology·2026
See all related articles

Administration of anti-ARTC2 nanobody (S+16a) prevents cell death during tissue processing. This method impacts CD44midTreg cell phenotype but preserves eTreg stability, aiding population recovery in immunological studies.

Area of Science:

  • Immunology
  • Cell Biology
  • Biotechnology

Background:

  • Flow cytometry and cell sorting are crucial techniques in immunological studies.
  • Tissue processing can lead to cell death, potentially affecting experimental outcomes.
  • Existing guidelines need updates to incorporate novel methods for preserving cell integrity.

Purpose of the Study:

  • To update guidelines for flow cytometry and cell sorting in immunological studies.
  • To evaluate the efficacy of anti-ARTC2 nanobody (S+16a) in preventing cell death during tissue processing.
  • To assess the impact of S+16a treatment on specific regulatory T cell (Treg) populations.

Main Methods:

  • Administration of anti-ARTC2 nanobody (S+16a) prior to tissue processing.
  • Analysis of cell viability and phenotype using flow cytometry.

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.1K
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

9.1K

Related Experiment Videos

Last Updated: Jan 8, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.2K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.1K
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

9.1K
  • Comparison of Treg populations (CD44midTreg and eTreg) before and after S+16a treatment.
  • Development of protocols for Treg population recovery.

    • Main Results:

    • S+16a treatment significantly reduced cell death during tissue processing.
    • The phenotype of CD44midTreg cells was significantly impacted by S+16a treatment.
    • The eTreg cell phenotype remained stable following S+16a treatment.
    • Specific protocols were outlined for the recovery of affected Treg populations.

    Conclusions:

    • Anti-ARTC2 nanobody (S+16a) is effective in preserving cell viability during tissue processing for immunological studies.
    • While S+16a impacts CD44midTreg phenotype, it maintains eTreg stability, offering a valuable tool for cell sorting.
    • The study provides updated protocols for flow cytometry and cell sorting, enhancing the reliability of Treg analysis.